Vaccibody.com | News
8
blog,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-13.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.5,vc_responsive

Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, today announces pre-clinical data supporting elicitation of strong killer T cell responses (CD8+ T cells) towards cancer neoantigens. The executive management is present at JP Morgan in San...

  Finalization of enrolment in the HPV16 therapeutic vaccine (VB10.16) phase IIa of trial VB C-01. Vaccibody AS announces that enrolment of patients will be finalised in December 2017 for the expansion phase (phase IIa) of its multicentre trial VB C-01. The enrolment goal was 15-20 patients...

Clinical Trial Application for VB10.NEO filed with PEI Vaccibody AS today announced filing of a Clinical Trial Application (CTA) for cancer neoantigen vaccine VB10.NEO with German regulatory authority Paul Ehrlich Institute (PEI). VB10.NEO is a personalized vaccine designed specifically for each patient and the neoantigen mutations...

Vaccibody AS today announced positive results from the phase I part of the clinical trial VB C-01. This trial is a first human dose, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by...

Vaccibody AS announced today vaccination of the first patient in its phase IIa study – an exploratory, open-label, multicenter study with VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human papillomavirus 16 (HPV 16). The phase I part of...

Vaccibody AS announces today that inclusion of patients in the expansion phase (phase IIa) of its multicentre trial VB C-01 can be initiated as the company was informed by Paul-Ehrlich Institut („PEI“), the German regulatory authorities, that an amendment to the IMPD (Investigational Medicinal Product...